Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin LymphomasSarah K. Knutson(Epizyme (United States)), Heike Keilhack(Epizyme (United States))PLoS ONEDecember 10, 201410.1371/journal.pone.0111840Cited by 74SaveCiteExport RISWatch citationsRelated PapersLiver‐specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks|The EMBO Journal|2008|265Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma|PLoS ONE|2016|76